Japanese pharma major Daiichi Sankyo would sell Ranbaxy Laboratories’ products in Venezuela under their hybrid business model, the two companies said on Wednesday. Daiichi Sankyo’s subsidiary — Daiichi Sankyo Venezuela SA — would begin marketing products of Ranbaxy, which has been marketing its drugs in Venezuela through a local distributor, the two firms said. The Venezuelan drug market is the third largest in Latin America, it said.